Supreme Court Seems Unconvinced USPTO Should Receive Attorneys' Fees In District Court Litigation
Executive Summary
Justices question why it took 170 years for the patent office to seek attorneys' fees from patent applicants who challenge its decisions in district court; USPTO acknowledges the delay is 'atmospherically unhelpful.'
You may also be interested in...
US ‘Blocking-Patent’ Doctrine Comes Under Attack
A US court doctrine that has invalidated patents covering major drugs such as Ampyra and Restasis is under attack from petitions to the US Supreme Court filed by Acorda and Allergan.
Decade In Review: Biopharma's Shifting Legal Landscape
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
US FDA's Decade In Review: From Biosimilars To Real-World Evidence
A look back over FDA actions during the past 10 years shows the evolution of its policies on opioids, preemption, off-label promotion and use of real-world evidence.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: